Share this article
Share this article
Fagron North America, a global leader in pharmaceutical compounding, debuts the most advanced genetic test supporting medical practitioners’ assessment and treatment of hair loss in the US: TrichoTest.
Fagron North America. Together we create the future of personalizing medicine.
AUSTIN, Texas, June 2, 2021 /PRNewswire/ Fagron North America, a global leader in pharmaceutical compounding, debuts the most advanced genetic test supporting medical practitioners assessment and treatment of hair loss in the US: TrichoTest.
TrichoTest is a genetic test performed on patients DNA that analyzes 13 genes and 48 genetic variations related to alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium. This genetic test is based on state-of-the-art DNA microarray technology and utilizes a patented algorithm to provide a personalized treatment recommendation to medical practitioners from 175 million therapeutic alterna